Clinical Research Directory

Inclusion Criteria: 1. Voluntarily participates and signs an informed consent form. 2. Aged 18-70 years, male or non-pregnant female. 3. Pathologically confirmed nasopharyngeal non-keratinizing carcinoma (differentiated or undifferentiated, i.e., WHO Type II or III). 4. Staging of any T, N2-3 or T4N1 (9th AJCC/UICC staging), with no distant metastasis. 5. ECOG performance status score of 0-1. 6. Hemoglobin (HGB) ≥90 g/L, neutrocyte count≥1.5×10⁹/L, platelets (PLT) ≥100×10⁹ /L. 7. Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×upper limit of normal (ULN), and bilirubin ≤ 1.5×ULN. 8. Adequate renal function: creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula). 9. Women of childbearing potential (WOCBP) who are sexually active must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug. Men who are sexually active with WOCBP must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug. Exclusion Criteria: 1. Age \> 70 years or \< 18 years. 2. Patients with recurrence or distant metastases. 3. Pathologically confirmed nasopharyngeal keratinizing squamous cell carcinoma (WHO Type I). 4. Patients who have previously undergone radiotherapy or systemic chemotherapy. 5. Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA \>1000 copies/ml or 200IU/ml. 6. Hepatitis C virus (HCV) antibody positive. 7. Has active autoimmune disease, except type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia). 8. Has any condition that required systemic corticosteroid (equivalent to prednisone \>10mg/d) or other immunosuppressive therapy within 28 days before informed consent. Patients who received systemic corticosteroid equivalent to prednisone ≤10mg/d, inhale or topical corticosteroids will be allowed. 9. Has a known history of active bacillus tuberculosis within 1 year; patients with adequately treated active bacillus tuberculosis over 1 year ago will be allowed. 10. Has a known history of interstitial lung disease. 11. Has received a live vaccine within 30 days before informed consent or will receive a live vaccine in the near future. 12. Is pregnant or breastfeeding. 13. Prior malignancy within 5 years, except in situ cancer, adequately treated non-melanoma skin cancer and papillary thyroid carcinoma. 14. Has known allergy to large molecule protein products or any compound of toripalimab. 15. Has a known history of human immunodeficiency virus infection. 16. Any other condition, including symptomatic heart failure, unstable angina, myocardial infarction, active infection requiring systemic therapy, mental illness, or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study or interferes with the interpretation of the results.